Amanda L. Sharpe, Ph.D.

Assistant Professor

Pharmaceutical Sciences

Phone (405) 271-6593 x47243

Fax (405) 271-7505



List of current grants

The Sharpe lab is interested in understanding the contribution of neuropeptides such as proopiomelanocortin, neurotensin, and corticotropin releasing factor to addiction, obesity, and age-related cognitive impairment, and in the development of therapeutics to treat these conditions. We use behavioral (operant conditioning), anatomical, pharmacological, and molecular approaches to address our research questions, often in combination with genetic mouse models. We are interested in the normal physiological role for these neuropeptides, as well as the adaptations that occur in this neurocircuitry under the conditions of obesity, food restriction, and chronic drug use. The long-term goals of our lab are to 1) elucidate the pharmacology and neurocircuitry involved in the regulation of appetite for and consumption of rewards (both food and drug), and 2) to determine the contribution of hypothalamic neuropeptides to age-related conditions such as obesity and cognitive decline.

Education & Experience

B.S. in Pharmacy

Ohio Northern University, Ada, OH


Ph.D. in Pharmacology

Wake Forest University, Winston-Salem, NC


Postdoc in Behavioral Neuroscience

Oregon Health & Science University, Portland, OR



Effect of obesity on proopiomelanocortin regulation of reward and feeding

Presbyterian Health Foundation

07/01/2018 - 06/30/2019

Effects of dietary restriction on age-related neurophysiological adaptations: From behavior to single dopaminergic neurons

Oklahoma Medical Research Foundation

05/01/2018 - 04/30/2021

Publications & Presentations

<< 1 2 3 4 5 > >>
    6. Dominguez-Lopez S, Piccart E, Lynch W B, Wollet M B, Sharpe A, Beckstead M J. Antagonism of neurotensin receptors in the ventral tegmental area decreases methamphetamine self-administration and methamphetamine seeking in mice. The international journal of neuropsychopharmacology. 2017

    7. Sharpe A, Varela E, Beckstead M J. Systemic PD149163, a neurotensin receptor 1 agonist, decreases methamphetamine self-administration in DBA/2J mice without causing excessive sedation. PloS one. 2017; 12 : e0180710

    8. McCall N M, Kotecki L, Dominguez-Lopez S, de Marron Fernandez Velasco E, Carlblom N, Sharpe A, Beckstead M J, Wickman K. Selective Ablation of GIRK Channels in Dopamine Neurons Alters Behavioral Effects of Cocaine in Mice. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2017; 42 : 707-715

    9. Bardgett M E, Sharpe A, Toney G M. Activation of corticotropin-releasing factor receptors in the rostral ventrolateral medulla is required for glucose-induced sympathoexcitation. American journal of physiology. Endocrinology and metabolism. 2014; 307 : E944-53

    10. Sharpe A, Varela E, Bettinger L, Beckstead M J. Methamphetamine self-administration in mice decreases GIRK channel-mediated currents in midbrain dopamine neurons. The international journal of neuropsychopharmacology. 2014; 18

<< 1 2 3 4 5 > >>